241467-58-3

Basic information

• Product Name: 2-[(1,1-Dimethylethoxy)carbonyl]-1-[[4'-nitro-(1,1'-biphenyl)-4-yloxy]methyl]-6,7-bis(phenylmethoxy)-1,2,3,4-tetrahydroisoquinoline
• CAS NO: 241467-58-3
• Molecular Weight: 672.778
• Mol File: 241467-58-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 2-[(1,1-Dimethylethoxy)carbonyl]-1-[[4'-nitro-(1,1'-biphenyl)-4-yloxy]methyl]-6,7-bis(phenylmethoxy)-1,2,3,4-tetrahydroisoquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(1,1-Dimethylethoxy)carbonyl]-1-[[4'-nitro-(1,1'-biphenyl)-4-yloxy]methyl]-6,7-bis(phenylmethoxy)-1,2,3,4-tetrahydroisoquinoline(241467-58-3)
• EPA Substance Registry System: 2-[(1,1-Dimethylethoxy)carbonyl]-1-[[4'-nitro-(1,1'-biphenyl)-4-yloxy]methyl]-6,7-bis(phenylmethoxy)-1,2,3,4-tetrahydroisoquinoline(241467-58-3)

Safety Data

• Hazardous Substances Data: 241467-58-3(Hazardous Substances Data)

Upstream product

• 171364-83-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)nitrobenzene 

Downstream Products

• 241467-59-4 1-{4'-[4-(3-hexyl-ureido)-benzenesulfonylamino]-biphenyl-4-yloxymethyl}-6,7-dihydroxy-3,4-dihydro-1H-isoquinoline-2-carboxylic acid tert-butyl ester 

Relevant articles and documents

Fused piperidine substituted arylsulfonamides as beta 3-agonists

Fused piperidine substituted arylsulfonamides are beta 3 adrenergic receptor agonists with very little beta 1 and beta 2 adrenergic receptor activity and as such the compounds are capable of increasing lipolysis and energy expenditure in cells. The compounds thus have potent activity in the treatment of Type II diabetes and obesity. The compounds can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compounds can be used to reduced neurogenic inflammation or as antidepressant agents. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.